BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for
60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment -
period adjusted according to the patient's body weight to a total minimum dose of 12g
(corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces
morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC).
The BENEFIT study is being conducted by the Population Health Research Institute (in
Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil)
together with a Steering Committee, and an independent Safety Monitoring Board.
Phase:
Phase 3
Details
Lead Sponsor:
Population Health Research Institute
Collaborators:
Canadian Institutes of Health Research (CIHR) Instituto Dante Pazzanese de Cardiologia University of Sao Paulo World Health Organization